Nordic biotech companies are invited to a focused breakfast webinar hosted by INNOSIAMO, a Basel-based biotech consultancy grounded in Nordic values.

Switzerland is one of the world’s strongest biotech hubs – powered by a concentrated innovation ecosystem, global pharma leadership, robust capital markets, and a world-leading environment for R&D, clinical development, and manufacturing. Swiss Biotech Day (SBD) in Basel has rapidly become a premier global meeting point, bringing together +3000 life science leaders, investors, and innovators from more than 40 countries.

This webinar will highlight the concrete opportunities available to Nordic companies at Swiss Biotech Day 2026, 4.-5. May in Basel, and why joining the Nordic delegation at the Global Village is a unique, longer-term strategic advantage. We will explore how a coordinated Nordic presence in Switzerland can help:

• Strengthen a shared Nordic narrative globally
• Increase visibility and international positioning
• Enable cross-border R&D partnerships and clinical validation pathways
• Support manufacturing collaborations
• Accelerate capital access and deal-flow
• Deepen relationships between the Nordic and Swiss biotech ecosystems

The session will also introduce how the Nordic delegation contributes to building a more unified and connected Nordic biotech ecosystem—one that collaborates internationally with greater strategic intent.

From Lab to Market: Protecting Biotech Innovations

VOSSIUS and Bio^M cordially invite you to our Biotech & IP Seminar 2026 in Munich tailored for biotechnology startups and founders, designed to explore the critical intersection of innovation, intellectual property, and business strategy.

Topics will include:

• Basics of patentability of biotech inventions
• Financing of startups
• Freedom-to-operate issues
• International and domestic licensing
• Issues with the Employee Inventions Act
• AI in inventions and patent law
• Strategic filings
• Copyright issues
• A U.S. perspective
• SPCs and regulatory affairs

We are delighted to announce that our patent attorneys and attorneys-at-law from VOSSIUS are joined by external guest speakers who are experts in the field of biotechnology, patent law, and startup funding. Their expertise will provide valuable insights into the challenges and opportunities facing today’s biotech innovators.

The event is an excellent opportunity to network with fellow founders, gain critical knowledge, and address the unique challenges your startup may face as you navigate the complexities of intellectual property in the biotechnology and life sciences sector.

Catering Fee: EUR 40.00

Attendees Bonus: All participants of the two-day seminar will be entered into a draw to win an iPad.

REVIVE webinar in collaboration with CF AMR Syndicate.

Speakers:

• Jane Davies, Professor of Paediatric Respirology and Experimental Medicine, National Heart and Lung Institute, Imperial College London (UK)
• Neill Gingles, Lead Scientist, Medicines Discovery Catapult (UK)
• David Richards, Chief Executive Officer, Clarametyx (USA)

Moderator:

• Deborah O’Neil, Chief Executive Officer, NovaBiotics Ltd (UK)

Chronic respiratory infections remain one of the most serious and persistent challenges in the care of people with cystic fibrosis (CF), even in the era of CFTR modulator therapy . This webinar brings together clinical experts, product developers, and innovators to explore the evolving infectious disease landscape in CF—focusing on the urgent need for novel antimicrobials, prioritizing difficult to treat Pseudomonas, Burkholderia, and NTM infections. It will highlight the unmet clinical needs, examine how well-designed target product profiles (TPPs) can guide meaningful innovation, and explore real-world challenges and opportunities in antimicrobial discovery and development for the CF community.

Presentation 1: The Clinical Picture of CF Infections: Why We Need New Antimicrobials (Jane Davies)
The lives of many people with CF have improved enormously with the advent of CFTR modulator drugs. These drugs do not however eradicate chronic lung infections, which persist and cause inflammation and structural lung damage. Similarly, pulmonary exacerbations are reduced in number, but not prevented completely. Current antimicrobial drugs have not been designed with the environment of the CF airway in mind, and are only partially effective.

Presentation 2: Shaping Innovation Together: Designing and implementing Patient-Centric Target Product Profiles (TPPs) (Neill Gingles)

• Overview and mission of the CF AMR Syndicate
• Aligning the goals for drug development with the needs of people with CF – development of patient-centric TPPs
• Implementation of TPPs via the Collaborative Discovery Programme

Presentation 3: Perspectives from Innovators: Navigating the CF Drug Discovery Landscape and the unique Challenges and opportunities in CF (David Richards)

• Unique dynamics in addressing the burden of CF
• Therapeutic strategies that can intervene in multiple mechanisms
• Progress with anti-biofilm approach CMTX-101

This live webinar including an interactive Q&A session was broadcast on 19 February 2026.

If you have questions or comments, please let us know: This email address is being protected from spambots. You need JavaScript enabled to view it..

The German Biotech Days (DBT *) bring together entrepreneurs with scientists and partners from politics, investors, funding institutions and administration.

Ticketing for DBT 2026 is now live! Secure your spot and become part of the Community of Innovators.

Subscribe to our mailing list for regular DBT updates.

Europe’s biotech sector continues to face significant financing challenges, especially during growth and scale‑up. As the EU moves forward with the landmark Biotech Act, this webinar explores the funding tools available today, how companies can access them, and what changes are needed to expand investment in European biotech.

The session will provide an overview of current EU public and blended finance options across the development pipeline, explain how the European Investment Bank evaluates and supports biotech projects, and offer first-hand insights from a biotech founder on securing funding from idea to market. It will also examine how upcoming EU initiatives could improve access to capital and attract more private investment.

Speakers include

Felicitas Riedl, Director of Innovation and Competitiveness at the European Investment Bank

Raffael Wohlgensinger, Founder & CEO, Formo

Jessica Martinsson, our moderator and CEO of SwedenBIO, the Swedish Biotech Association

The drumbeat of bad news that has afflicted the venture community in biotech for several years now has been replaced by a more hopeful tune. Endpoints News and DealForma have partnered once again to produce a detailed look at the numbers driving venture investing today. And we’ll be hosting our annual webinar with several top investors to gauge how the field is rolling out their strategies for the year ahead. Moderated by Endpoints News founding editor John Carroll.

The next ECRD will be held on 3 & 4 June 2026 in Prague and will be titled “Rare Diseases in a Changing & Competitive Europe: Shaping policies to address the unmet needs of people living with rare diseases”.  

The European Conference on Rare Diseases & Orphan Products (ECRD) is the largest patient-led policy-shaping event on rare diseases in Europe. 

By bringing together people living with rare diseases and patient advocates alongside policymakers, healthcare industry representatives, clinicians, regulators, and Member State officials, EURORDIS leverages the strength of this unique network to advance goal-driven policies that improve the lives of people living with a rare disease and their families. 

ECRD 2026 is expected to unite over 500 participants in Prague, with an additional 300+ joining online. Thanks to its hybrid format, the conference will provide an unparalleled platform for connection and collaboration, enabling participants across the rare disease community to exchange knowledge, share experiences, and build partnerships. 

Discover the programme here.

Participants who register before 26 February 2026 will benefit from our exclusive Early-Bird rates. 

Register here.

Theme: Strengthening Regulatory Practices on Labelling for Antimicrobials to promote appropriate use and disposal – A One Health Perspective

The Quadripartite Joint Secretariat will convene the Second Global Regulatory Authorities Summit on Antimicrobial Resistance (AMR) on 14–15 January 2026, to be held virtually. The Summit will provide a platform for regulatory authorities to share practical experience and lessons learned, with a particular focus on regulatory practices for antimicrobial labelling to promote appropriate use and safe disposal from a One Health perspective.  

For further information, please refer to the Concept Note and Provisional Agenda.

This collaboration between Florent VC and the KTH AI Society (KTHAIS) spotlights emerging founders and builders before a curated audience of leading engineers, founders, and investors. Over 24 hours, 45–60 of Stockholm’s best builders will create practical AI agents and orchestration systems—tools that make you (or people like you) meaningfully more productive.

Theme

Build Your AI Co-worker

In 24 hours, build an AI agent that makes builders 10× more productive.

Date | February 7–8, 2025 (Saturday–Sunday)

Venue | Stockholm TBA

Participants | 45–60 builders (15 teams of 3–4)

Prizes | SEK 100,000 total

The challenge

Build an agent that helps you code, debug, test, research, or ship faster. The focus is on orchestration and real workflows, not training models from scratch.

Guidelines

Developer productivity

PR review, testing/edge cases, auto-updating docs, deploy helpers.

Research & learning

Paper synthesis with citations, contradiction-finders, adaptive learning tools.

Multi-agent orchestration

Teams of agents that coordinate, delegate, and execute complex tasks.

Support & upside

• Pre-loaded API credits (Lovable, Gemini, Azure) plus starter templates and frameworks.
• Optional workshops on agent building and multi-agent patterns.
• Mentors and judges include Florent partners with world-class product experience.
• Top projects may continue beyond the weekend, including potential Florent support.